(PPHM, OWW, DSCO) CRWENewswire Stocks In Action

Good Morning, Its Tuesday December 6th, 2011, I’m Christina Collins with CRWENewswire Stocks In Action. Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients. Orbitz Worldwide Inc - OWW - was upgraded from Hold to Buy by Brokerage Firm The Benchmark Company. and lastly; Discovery Laboratories Inc - DSCO - released new data showing that use of its AFECTAIR resulted in as much as a 70 percent reduction in the amount of nitric oxide required to deliver the desired dose of the therapeutic gas when compared with current standard of care. Thank you for joining me and have a great day! For CRWE Newswire, Stocks In Action, I’m Christina Collins